The stock is a leveraged proxy on ZEC price with a biotech catalyst option. The FDA alignment on a Phase 3 trial for sirexatamab is a meaningful de-risking event for the Leap subsidiary, but the strategic process introduces binary outcome risk. Monitor ZEC price action for near-term direction; the Phase 3 trial initiation and any partnership/spin-out announcement for sirexatamab are the next key catalysts.
Price Chart
Executive Summary
Cypherpunk Technologies reported Q2 2026 net income of $39.4M ($0.18 diluted), swinging from a $16.6M net loss in Q2 2025, driven entirely by a $46.0M unrealized gain on ZEC treasury holdings as ZEC rose from $243.35 to $400.09. The company increased ZEC holdings to 323,394.38 ZEC (1.92% of circulating supply) and its Leap Therapeutics subsidiary reached FDA alignment on a registrational Phase 3 trial for sirexatamab in DKK1-high colorectal cancer, while initiating a strategic process to advance the asset. The reported net income is non-cash and entirely dependent on ZEC price volatility, masking a $4.7M operating loss and a cash burn of $2.7M in operating activities for the quarter.
Key Financial Metrics
Key Facts
- Net income of $39.4M ($0.18 diluted) vs net loss of $16.6M in Q2 2025, driven by a $46.0M unrealized gain on ZEC holdings
- ZEC treasury holdings increased to 323,394.38 ZEC at avg price of $341.83, representing 1.92% of circulating supply
- Cash and cash equivalents totaled $7.6M at June 30, 2026, down from $14.0M at Dec 31, 2025
- Operating cash burn was $2.7M in Q2 2026, improved from $14.5M in Q2 2025
- Leap Therapeutics reached FDA alignment on a registrational Phase 3 trial for sirexatamab in DKK1-high mCRC
- Leap initiated a strategic process to advance sirexatamab, potentially as a spin-out or via partnership
- DeFianCe Phase 2 study published in Clinical Cancer Research; primary endpoint not met in ITT but strong signal in DKK1-high subgroup
- Common shares outstanding increased to 107.8M from 83.9M at Dec 31, 2025, reflecting dilution
Financial Impact
Net income of $39.4M is entirely non-cash (ZEC mark-to-market); operating loss of $4.7M and cash burn of $2.7M. ZEC holdings valued at $129.4M at quarter-end.
Risk Factors
- ZEC price volatility directly drives reported earnings and asset values; a decline would reverse the reported net income
- Cash runway is limited ($7.6M); the strategic process for sirexatamab may require dilutive financing
- Phase 3 trial for sirexatamab may fail to replicate Phase 2 biomarker results; FDA alignment does not guarantee approval
- Significant share dilution (shares outstanding up 28% from Dec 2025) pressures per-share metrics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094445 |
| Document: tm2622925d1_ex99-2.htm | 0001104659-26-094445 |
| Document: tm2620947d1_8k.htm | 0001104659-26-094445 |
| Document: 0001104659-26-094445-index-headers.html | 0001104659-26-094445 |
| Document: 0001104659-26-094445-index.html | 0001104659-26-094445 |
| Document: 0001104659-26-094445.txt | 0001104659-26-094445 |
| 8-K Data (Synthetic) | 0001104659-26-094445 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Insider Cluster | $3.31 $2.83 | ▲ +14.50% | ▲ +14.47% | $3.13 (+5.29%) |
Sep 22, 2026 5w ago | Institutional Cluster | $3.73 $2.81 | ▼ −24.66% | ▼ −24.11% | $3.13 (−15.95%) |
Sep 22, 2026 5w ago | 8-K | $3.73 $2.81 | ▼ −24.66% | ▼ −24.11% | $3.13 (−15.95%) |
Aug 18, 2026 10w ago | 8-K | $0.8054 $2.44 | ▲ +202.96% | ▲ +204.70% | $3.13 (+289.25%) |
Aug 12, 2026 10w ago | 8-K | $0.6579 $2.20 | ▲ +234.40% | ▲ +236.30% | $3.13 (+376.52%) |
May 26, 2026 22w ago | 8-K | $1.16 $0.6168 | ▼ −46.83% | ▼ −44.88% | $3.13 (+170.26%) |
May 14, 2026 23w ago | 8-K | $1.20 $0.6500 | ▲ +45.83% | ▲ +44.98% | $3.13 (−161.25%) |
Apr 10, 2026 28w ago | 8-K | $0.9900 $1.10 | ▲ +11.11% | ▲ +3.38% | $3.13 (+216.67%) |
Mar 27, 2026 30w ago | 144 | $0.6570 $0.9250 | ▲ +40.79% | ▲ +28.05% | $3.13 (+377.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers